Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sophia GeneticsSOPH +15.25%73 EV-to-EBIT is -8.16 as of Aug. 08, 2026. GuruFocus rates SOPH with a GF Score™ of 73/100 and a GF Value™ of $5.09 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 471 Healthcare Providers & Services companies, Sophia Genetics ranks worse than 212314.01% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Sophia Genetics's Enterprise Value for the quarter that ended in Jun. 2026 was $380.21 Mil.
Sophia Genetics's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-73.68 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sophia Genetics EV-to-EBIT Related Terms
Sophia Genetics EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Sophia Genetics's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Sophia Genetics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sophia Genetics EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Sophia Genetics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Sophia Genetics's EV-to-EBIT falls into.
Sophia Genetics's current Enterprise Value is $600.99 Mil.
Sophia Genetics's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-73.68 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sophia Genetics (SOPH) has a EV-to-EBIT of -8.16 as of Aug. 08, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Sophia Genetics and its competitors. According to the industry distribution chart, Sophia Genetics ranks #999999 out of 471 companies in the Healthcare Providers & Services industry.
Is Sophia Genetics' EV-to-EBIT too high?
Sophia Genetics' current EV-to-EBIT is -8.16. Based on the distribution chart, Sophia Genetics ranks #999999 out of 471 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Sophia Genetics has a GF Score™ of 73/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sophia Genetics' EV-to-EBIT compare to EVH and NRC?
According to the Healthcare Providers & Services industry distribution chart, Sophia Genetics ranks #999999 out of 471 companies for EV-to-EBIT. This places Sophia Genetics in the lower half of its industry. The industry median EV-to-EBIT is 16.04. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Healthcare Providers & Services company?
The median EV-to-EBIT among Healthcare Providers & Services companies is 16.04, based on 471 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Sophia Genetics and its competitors. For the Healthcare Providers & Services industry, the median EV-to-EBIT is 16.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sophia Genetics's current EV-to-EBIT is -8.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sophia Genetics stock overvalued right now?
Based on GuruFocus' analysis, Sophia Genetics (SOPH) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.09, compared to a current price of $7.68 — trading 50.9% above its estimated fair value. The current EV-to-EBIT is -8.16. Sophia Genetics' overall GF Score™ is 73/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Sophia Genetics (SOPH), the current EV-to-EBIT is -8.16 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sophia Genetics (SOPH) Overvalued in 2026?
Based on GuruFocus' analysis, Sophia Genetics stock appears to be overvalued.
The current stock price of $7.68 is trading 50.9% above its estimated GF Value™ of $5.09.
GuruFocus considers Sophia Genetics to be Significantly Overvalued.
Key valuation signals for SOPH:
EV-to-EBIT: -8.16
GF Value™: $5.09 vs. price of $7.68 (50.9% above fair value)
No single metric tells the full story. See the SOPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
73GF Score
Get the complete analysis for SOPH
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SOPH has been successfully added to your 
